Trial Profile
A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Chordoma; Clear cell sarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Meningioma; Myxoid liposarcoma; Nerve sheath neoplasms; Osteosarcoma; Perivascular epithelioid cell tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
- Focus Therapeutic Use
- 24 Apr 2023 Status changed from active, no longer recruiting to completed.
- 29 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 12 Feb 2021 Planned End Date changed from 1 Mar 2023 to 1 Dec 2022.